Company Overview

Silicon Valley Acquisition Corp. (SVAQ) was a U.S.-based special purpose acquisition company (SPAC) formed to raise capital through an initial public offering and complete a merger or similar business combination with an operating company. As a SPAC, SVAQ did not conduct traditional commercial operations; its sole business purpose was to identify, evaluate, and acquire a target company, typically in the technology, healthcare, or life sciences sectors, where its sponsors believed they could add strategic and operational value.

SVAQ completed its initial public offering in 2013 and subsequently entered into a business combination with Roivant Sciences Ltd., a biopharmaceutical company focused on developing and commercializing drug candidates acquired from other pharmaceutical firms. Following the completion of the transaction in 2014, SVAQ ceased to exist as an independent public entity and was renamed Roivant Sciences Ltd. Public information after the merger is reported under Roivant Sciences rather than SVAQ. Data inconclusive based on available public sources regarding any material activities by SVAQ beyond this transaction.

Business Operations

Prior to its merger, Silicon Valley Acquisition Corp. had no operating revenues and no commercial products or services. Its operations consisted primarily of capital management, regulatory compliance, target screening, due diligence, and transaction execution activities typical of a SPAC structure. Funds raised in the IPO were held in trust and invested in short-term U.S. government securities pending completion of a qualifying acquisition or liquidation.

Upon completion of the merger with Roivant Sciences Ltd., the operating business became Roivant’s pharmaceutical development platform, and SVAQ’s SPAC structure was dissolved. As a result, SVAQ has no ongoing domestic or international operations, assets, or revenue-generating activities separate from Roivant. Data inconclusive based on available public sources regarding any additional subsidiaries or joint ventures held directly by SVAQ prior to the merger.

Strategic Position & Investments

SVAQ’s strategic direction was singular and time-bound: to complete a value-accretive business combination within the timeframe defined in its SEC filings. Its investment strategy focused on identifying a private company with scalable growth potential and public-market readiness. The merger with Roivant Sciences Ltd. represented the execution of this strategy and was SVAQ’s only material investment.

Following the transaction, all strategic initiatives, acquisitions, and technology investments were undertaken by Roivant Sciences rather than SVAQ. Public disclosures do not indicate that SVAQ pursued or completed any other acquisitions or portfolio investments prior to its dissolution. Data inconclusive based on available public sources regarding alternative targets evaluated but not consummated.

Geographic Footprint

Before the merger, Silicon Valley Acquisition Corp. was incorporated in the United States and listed on a U.S. securities exchange, with administrative functions conducted primarily in the United States. As a SPAC, it did not maintain operational facilities, manufacturing sites, or an international operating footprint.

After the business combination, the geographic presence became that of Roivant Sciences Ltd., which operates across North America, Europe, and Asia through its pharmaceutical subsidiaries. These operations are attributable to Roivant rather than SVAQ as a standalone entity.

Leadership & Governance

SVAQ was sponsored and managed by a team with experience in investment management and corporate transactions. Governance prior to the merger followed a standard SPAC structure, with a board of directors overseeing management’s execution of the acquisition mandate. Following the merger, SVAQ’s board and management were replaced by the leadership of Roivant Sciences Ltd.

Key executives associated with SVAQ prior to the merger included:

• Alexander J. Denner – Chief Executive Officer
• Vivek Ramaswamy – Co-founder of Roivant Sciences Ltd. and post-merger executive
• Daniel O’Connor – Chief Financial Officer

Public sources consistently identify Alexander J. Denner as the principal executive leading SVAQ through its IPO and merger process. Specific details on broader executive roles and internal governance committees are limited; data inconclusive based on available public sources.